Sees FY24 net cash burn $110M-$130M. Cash position at March 31, 2024, is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
- Compass Pathways to announce first quarter financial results on May 8, 2024
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Compass Pathways enters psilocybin research collaboration with Mindful Health
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment